Form 8-K - Current report:
SEC Accession No. 0001193125-22-171424
Filing Date
2022-06-10
Accepted
2022-06-10 06:05:55
Documents
16
Period of Report
2022-06-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d300771d8k.htm   iXBRL 8-K 25563
2 EX-99.1 d300771dex991.htm EX-99.1 25592
3 EX-99.2 d300771dex992.htm EX-99.2 25406
7 GRAPHIC g300771g0610025507345.jpg GRAPHIC 9329
8 GRAPHIC g300771g0610025815721.jpg GRAPHIC 9329
  Complete submission text file 0001193125-22-171424.txt   245295

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA imgo-20220610.xsd EX-101.SCH 2849
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE imgo-20220610_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imgo-20220610_pre.xml EX-101.PRE 11703
10 EXTRACTED XBRL INSTANCE DOCUMENT d300771d8k_htm.xml XML 3484
Mailing Address 329 OYSTER POINT BLVD., 3RD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 329 OYSTER POINT BLVD., 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 (415) 529-5055
Imago BioSciences, Inc. (Filer) CIK: 0001623715 (see all company filings)

EIN.: 454915810 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40604 | Film No.: 221007567
SIC: 2834 Pharmaceutical Preparations